berzosertib + avelumab + carboplatin

This drug is a combination regimen of the small molecule ATR kinase inhibitor **berzosertib** (M6620, VX-970, VE-822), the anti-PD-L1 monoclonal antibody **avelumab** (Bavencio), and the platinum-based chemotherapy **carboplatin**. - **Berzosertib** is an intravenous, highly selective inhibitor of the DNA damage response kinase ATR (ataxia telangiectasia and Rad3-related), thought to sensitize tumor cells to DNA-damaging agents by preventing effective repair and checkpoint activation, leading to synthetic lethality in p53/ATM-deficient and other genomically unstable tumor cells. - **Avelumab** is a fully human monoclonal IgG1 antibody targeting programmed death-ligand 1 (**PD-L1**), functioning as a checkpoint inhibitor to enhance antitumor immune response. - **Carboplatin** is a second-generation platinum-based cytotoxic chemotherapeutic that forms DNA cross-links, leading to apoptosis in rapidly dividing cells. This triple combination was studied in clinical trials for platinum-resistant ovarian cancer, especially after PARP inhibitor resistance, to synergistically induce cancer cell death via immunotherapy, DNA damage, and checkpoint disruption. The phase II trial in PARP-inhibitor-resistant platinum-sensitive ovarian cancer was terminated after the end of a phase Ib portion.

Other names

avelumabcarboplatin